Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Apremilast

An oral phosphodiesterase 4 (PDE4) inhibitor that raises cyclic AMP inside cells and dampens the production of inflammatory molecules: approved in the United States in 2014 for psoriatic arthritis and plaque psoriasis, and in 2019 for the oral ulcers of Behçet's disease. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It was born as a thalidomide analogue, sharing its phthalimide ring; unlike thalidomide, however, it does not bind the protein cereblon, because it lacks the glutarimide ring.

ApremilastGo to the active ingredient →
ApremilastActive ingredientApremilastCat. No. P-A175-001CAS 608141-41-9
Apremilast-d5Isotopically labelledApremilast-d5Cat. No. P-A175-005CAS 1258597-47-5
Apremilast-d8Isotopically labelledApremilast-d8Cat. No. P-A175-006CAS 1258597-45-3

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.